331.61
price up icon1.32%   4.31
 
loading
前日終値:
$327.30
開ける:
$326.55
24時間の取引高:
196.95K
Relative Volume:
0.67
時価総額:
$9.82B
収益:
$417.30M
当期純損益:
$225.03M
株価収益率:
44.32
EPS:
7.4815
ネットキャッシュフロー:
$237.38M
1週間 パフォーマンス:
+2.89%
1か月 パフォーマンス:
-4.73%
6か月 パフォーマンス:
+28.37%
1年 パフォーマンス:
+75.68%
1日の値動き範囲:
Value
$323.87
$333.56
1週間の範囲:
Value
$319.58
$339.69
52週間の値動き範囲:
Value
$179.19
$382.54

Krystal Biotech Inc Stock (KRYS) Company Profile

Name
名前
Krystal Biotech Inc
Name
セクター
Healthcare (1050)
Name
電話
(412) 586-5830
Name
住所
2100 WHARTON STREET, PITTSBURGH, PA
Name
職員
295
Name
Twitter
@KrystalBiotech
Name
次回の収益日
2026-11-02
Name
最新のSEC提出書
Name
KRYS's Discussions on Twitter

Compare KRYS vs VRTX, MRNA, REGN, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KRYS icon
KRYS
Krystal Biotech Inc
331.61 9.82B 417.30M 225.03M 237.38M 7.4815
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
510.08 129.29B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
225.00 89.83B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
746.54 76.86B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
825.03 51.88B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
189.76 40.67B 742.00K -1.37B -1.07B -7.0731

Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-09-24 再開されました Goldman Buy
2026-08-14 開始されました RBC Capital Mkts Outperform
2026-03-27 開始されました Wolfe Research Peer Perform
2026-01-06 アップグレード Citigroup Neutral → Buy
2025-03-05 開始されました Jefferies Buy
2024-08-06 ダウングレード Citigroup Buy → Neutral
2023-11-20 開始されました Goldman Buy
2023-10-24 開始されました Cantor Fitzgerald Overweight
2023-10-12 開始されました Citigroup Buy
2023-09-07 開始されました Berenberg Buy
2023-04-18 開始されました Stifel Buy
2023-02-28 アップグレード Goldman Neutral → Buy
2022-08-25 ダウングレード Goldman Buy → Neutral
2022-01-18 開始されました BofA Securities Buy
2021-07-20 アップグレード Goldman Neutral → Buy
2020-09-18 開始されました B. Riley FBR Buy
2020-06-04 開始されました Evercore ISI Outperform
2019-09-24 開始されました Goldman Neutral
2019-08-06 繰り返されました H.C. Wainwright Buy
2019-06-24 繰り返されました Chardan Capital Markets Buy
2019-06-24 繰り返されました H.C. Wainwright Buy
2019-05-30 開始されました Guggenheim Buy
2018-09-11 開始されました Cantor Fitzgerald Overweight
すべてを表示

Krystal Biotech Inc (KRYS) 最新ニュース

pulisher
Sep 17, 2026

Krystal Biotech (NASDAQ: KRYS) Grants Director Sutherland Everett Rand 1,658 Derivative Securities - Kalkine Media

Sep 17, 2026
pulisher
Sep 17, 2026

Krystal Biotech (NASDAQ: KRYS) Grants Director Janney Daniel 1,658 Derivative Securities at Zero Cost - Kalkine Media

Sep 17, 2026
pulisher
Sep 17, 2026

Krystal Biotech (NASDAQ: KRYS) Grants 1,658 Derivative Securities to Director Catherine Mazzacco - Kalkine Media

Sep 17, 2026
pulisher
Sep 17, 2026

Krystal Biotech (NASDAQ: KRYS) Grants 1,658 Derivative Securities to Director Mason Christopher - Kalkine Media

Sep 17, 2026
pulisher
Sep 16, 2026

Director at Krystal Biotech (KRYS) gets new stock options and RSUs - Stock Titan

Sep 16, 2026
pulisher
Sep 16, 2026

Krystal Biotech (KRYS) board member receives new options and RSUs - Stock Titan

Sep 16, 2026
pulisher
Sep 11, 2026

(KRYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Sep 11, 2026
pulisher
Sep 11, 2026

What Put Krystal Biotech (KRYS) in Focus? - Kalkine Media

Sep 11, 2026
pulisher
Sep 10, 2026

Krystal Biotech at Cantor healthcare conference: pipeline gains pace By Investing.com - Investing.com Canada

Sep 10, 2026
pulisher
Sep 10, 2026

KRYS: International expansion and pipeline progress set the stage for multi-product growth - TradingView

Sep 10, 2026
pulisher
Sep 10, 2026

Krystal Biotech at Cantor healthcare conference: pipeline gains pace - Investing.com

Sep 10, 2026
pulisher
Sep 10, 2026

Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga

Sep 10, 2026
pulisher
Sep 08, 2026

Krystal Biotech CEO Krishnan Krish S Sells 25,000 Shares at Prices Up to $366.56 on September 4, 2026 - Kalkine Media

Sep 08, 2026
pulisher
Sep 08, 2026

Krystal Biotech President Krishnan Suma Disposes of 25,000 Shares at $354.54-$366.56 (NASDAQ: KRYS) - Kalkine Media

Sep 08, 2026
pulisher
Sep 08, 2026

Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing - marketscreener.com

Sep 08, 2026
pulisher
Sep 08, 2026

Krystal Biotech Insider Sold Shares Worth $8,982,986, According to a Recent SEC Filing - marketscreener.com

Sep 08, 2026
pulisher
Sep 08, 2026

Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing - Yahoo Finance

Sep 08, 2026
pulisher
Sep 07, 2026

Top insider buys and sells disclosed for Friday - Investing.com

Sep 07, 2026
pulisher
Sep 07, 2026

Krystal Biotech, Inc. (KRYS) Stock Analysis: Unveiling a 7.47% Potential Upside with Promising Genetic Medicine Innovations - DirectorsTalk Interviews

Sep 07, 2026
pulisher
Sep 07, 2026

Top insider buys and sells disclosed for Friday By Investing.com - Investing.com Nigeria

Sep 07, 2026
pulisher
Sep 05, 2026

Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock By Investing.com - Investing.com South Africa

Sep 05, 2026
pulisher
Sep 04, 2026

Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock By Investing.com - Investing.com Australia

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com Nigeria

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock - Investing.com Nigeria

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock - Investing.com

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock By Investing.com - Investing.com South Africa

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com India

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock - Moomoo

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock - Moomoo

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech (KRYS) R&D head sells 25,000 shares under trading plan - Stock Titan

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech (NASDAQ: KRYS) CEO sells 25,000 shares under trading plan - Stock Titan

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech (NASDAQ: KRYS) holder to sell 25,000 founders shares - Stock Titan

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech (KRYS) insider moves to sell 2017 shares in a multimillion-dollar deal - Stock Titan

Sep 04, 2026
pulisher
Sep 04, 2026

Krystal Biotech stock steadies as regulatory debate over Vyjuvek intensifies - ad-hoc-news.de

Sep 04, 2026
pulisher
Sep 03, 2026

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? - TradingView

Sep 03, 2026
pulisher
Sep 03, 2026

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? - Zacks Investment Research

Sep 03, 2026
pulisher
Sep 03, 2026

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference - The Manila Times

Sep 03, 2026
pulisher
Sep 03, 2026

Krystal Biotech to Participate in 2026 Cantor Global Healthcare Conference - Quiver Quantitative

Sep 03, 2026
pulisher
Sep 03, 2026

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference - marketscreener.com

Sep 03, 2026
pulisher
Sep 03, 2026

A healthcare conference webcast is set for Sept. 10 in New York - Stock Titan

Sep 03, 2026
pulisher
Sep 02, 2026

Krystal Biotech stock gains on solid Q2 2026 Vyjuvek growth - ad-hoc-news.de

Sep 02, 2026
pulisher
Sep 02, 2026

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Sep 02, 2026
pulisher
Aug 31, 2026

Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings And 9.54% Potential Upside - DirectorsTalk Interviews

Aug 31, 2026
pulisher
Aug 25, 2026

Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga

Aug 25, 2026
pulisher
Aug 24, 2026

Krystal Biotech, Inc. (KRYS) Stock Analysis: Discovering a 11% Potential Upside in Biotech Innovation - DirectorsTalk Interviews

Aug 24, 2026
pulisher
Aug 23, 2026

Krystal Biotech Stock Soars 16% in Three Months: Here's Why - Eastern Progress

Aug 23, 2026
pulisher
Aug 21, 2026

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Aug 21, 2026
pulisher
Aug 20, 2026

Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600 - Eastern Progress

Aug 20, 2026

Krystal Biotech Inc (KRYS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Krystal Biotech Inc (KRYS) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
SUMA KRISHNAN
Director
Sep 04 '26
Proposed Sale
371.47
25,000
9,286,750
0
Krishnan Krish S
President and CEO
Sep 04 '26
Sale
359.32
25,000
8,983,084
1,347,543
KRISH KRISHNAN
Director
Sep 04 '26
Proposed Sale
371.47
25,000
9,286,750
0
Dino A. Rossi
Director
Aug 14 '26
Proposed Sale
332.27
25,000
8,306,750
0
ROSSI DINO A
Director
Aug 14 '26
Sale
329.12
25,000
8,227,953
50,000
Thomas John Charles
EVP, General Counsel
Jun 25 '26
Option Exercise
179.25
1,000
179,250
1,000
Thomas John Charles
Officer
Jun 25 '26
Proposed Sale
347.27
1,000
347,270
0
Thomas John Charles
EVP, General Counsel
Jun 25 '26
Sale
347.27
1,000
347,270
0
Krishnan Suma
President, R&D
Jun 04 '26
Sale
308.11
25,000
7,702,825
1,378,155
Krishnan Krish S
President and CEO
Jun 04 '26
Sale
308.12
25,000
7,702,984
1,450,253
$112.40
price up icon 2.84%
$143.73
price up icon 2.73%
$159.78
price up icon 5.08%
$54.80
price down icon 0.17%
$71.38
price up icon 9.79%
$62.75
price up icon 3.31%
大文字化:     |  ボリューム (24 時間):